Acculine CEO: ‘This test has the potential to save millions of lives a year.’
By Shula Rosen, United with Israel
Cardiovascular disease is the leading cause of death globally, and yet tests to detect the early signs of heart attack tend to be invasive, inconvenient, and costly.
Israeli healthcare startup Acculine is set to change that. With the help of advanced technology, it can detect heart attacks in early stages and save lives.
Acculine has developed CORA, a revolutionary system to assess a patient’s risk of heart disease.
CORA evaluates the heart’s electrical activity, oxygen saturation levels, and respiratory phase with instant results without waiting or invasive tests.
The four-minute exam can be performed in an outpatient clinic for greater efficiency, cost savings, and rapid delivery of life-saving diagnostic services.
Acculine is also in optimal financial health and has just raised $4.2 million in a seed round led by eHealth Ventures and Maccabi Healthcare Services.
Included in the amount is a grant from Israel’s Innovation Authority and Google’s AI Startup fund.
The funds raised will be used for further development of the CORA system.
The AccuLine was founded in early 2022 by four founders: CEO Moshe Barel, Prof. Aharon Frimerman, head of the Interventional Cardiology unit at Hillel Yaffe Medical Center, Prof. Shai Revzen, a computer science professor at the University of Michigan, and Benny Shani, the company’s CTO.
“Diagnosing patients at very early stages of risk for CAD without invasive testing will add value to patients, healthcare systems, doctors, and insurance organizations,” says Moshe Barel, co-founder and CEO of AccuLine.
“This test has the potential to save millions of lives a year and save hundreds of millions of dollars for healthcare systems on unnecessary tests or expensive treatments for patients after a heart attack, including rehabilitation and medication,” Barrel continued.
In tests, AccuLine successfully diagnosed patients with coronary heart disease, and the product is headed for FDA trials early next year.